CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Fort Worth’s oldest African American Baptist church, which was recently put on a list of Most Endangered Places in the city, ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.